This will be nowhere near 10x after Phase 1. Phase 1 is to see how safe this is in healthy patients. It has nothing to do with how effective this will be in stroke patients. Maybe after Phase 2 it might take off but that's after success, a few years and more dilution. Would like to see more diversification in their pipeline instead of just the one drug.
ARGENICA THERAPEUTICS LIMITED IPO Analysis, page-14
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
74.0¢ |
Change
-0.025(3.27%) |
Mkt cap ! $90.88M | |||
| Open | High | Low | Value | Volume |
| 77.0¢ | 77.0¢ | 73.5¢ | $80.11K | 106.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | 72.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 74.0¢ | 16805 | 1 |
View Market Depth
| Last trade - 15.56pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
74.0¢ |
Change
-0.025 ( 2.63 %) |
||||
| Open | High | Low | Volume | ||
| 76.5¢ | 76.5¢ | 73.5¢ | 42720 | ||
| Last updated 15.56pm 28/05/2024 ? | |||||
| AGN (ASX) Chart |